Earlier real-world data in adults aged 65 years and older showed absolute vaccine effectiveness against COVID-19–related hospitalization of 59.3% for mRNA-1283 and 48.3% for BNT162b2, although those authors noted that each vaccine was compared with its own unvaccinated group and the study was not designed as a head-to-head comparison. The current analysis offers a direct comparison between the 2 products.2,4
Limitations and Industry Support
Because the study was observational, the findings are associative, and residual confounding may remain from factors such as testing behavior, undocumented prior infection, and vaccine availability. Some negative-control outcomes also showed associations, although smaller than those for COVID-19. The predominantly older, male VHA population may limit generalizability.
The authors also emphasized that the results reflect added protection from one product over another, not the overall benefit of vaccination. Moderna supported the study and contributed to its design, interpretation, and manuscript preparation, although the company stated it did not conduct the study or collect, manage, or analyze the data.1-3
Implications for Pharmacists
Older adults continue to carry a substantial COVID-19 burden. The CDC estimates there were between 120,000 and 250,000 COVID-19 hospitalizations from October 2025 through early May 2026, yet only 31% of adults aged 65 to 74 years and 37% of those aged 75 years and older received a COVID-19 vaccine during the 2025-2026 season. The study authors suggested the findings may inform seasonal vaccine selection for high-risk older adults.2,5
When counseling patients, pharmacists should note that mRNA-1283 had a safety profile similar to mRNA-1273 in clinical trials, with fewer local reactions; the most common adverse effects were injection site pain, fatigue, headache, and myalgia.3
Expert Insights
In an interview with Pharmacy Times, Francesca Ceddia, MD, chief medical affairs officer at Moderna, talked about what the findings mean for pharmacists who vaccinate older adults against COVID-19.
Pharmacy Times: Most of the difference between mRNA-1283 and BNT162b2 accrued after 90 days. What might explain that pattern, and what does it suggest about the durability of protection and vaccine timing for older adults?
Francesca Ceddia, MD: One of the particularly interesting findings from this study is that the difference in protection between the two vaccines became more apparent over time, particularly after 90 days. This raises the possibility that mNEXSPIKE may offer an advantage in maintaining protection over time, which is especially relevant for older adults at greater risk of severe COVID-19 outcomes. While the study was not designed to evaluate differences in waning protection or the biological mechanisms underlying this finding, the results are encouraging and warrant further investigation.
From a public health perspective, these findings highlight the importance of maintaining protection throughout the respiratory virus season. Importantly, they should not be interpreted as a reason to delay vaccination but rather as additional evidence that may inform vaccine selection for older adults.
Pharmacy Times: Given the observational design, the predominantly male veteran population, and Moderna’s involvement, how should pharmacists weigh these findings when choosing a COVID-19 vaccine for patients aged 65 years and older?
Ceddia: Real-world evidence complements randomized clinical trials by helping us understand how vaccines perform in clinical practice. This study adds meaningful evidence from nearly 295,000 older adults in a population with a substantial burden of underlying medical conditions, placing many participants at increased risk of severe COVID-19 outcomes. In the population studied, mNEXSPIKE was associated with an estimated 35.9% greater relative effectiveness against medically attended COVID-19 and 47.0% against COVID-19-associated hospitalization compared with BNT162b2 over 150 days.
As an observational real-world analysis, the study is subject to residual confounding, including differences in testing behavior, undocumented prior infection, and vaccine availability. The predominantly older, male VHA population may limit generalizability to broader populations. Findings are associative and do not establish causality. While the study was supported by Moderna, independent academic investigators were responsible for conducting the research and analyzing the data.
For pharmacists, these results provide additional evidence in a clinically vulnerable population to be considered alongside the totality of available evidence, individual patient considerations, and current recommendations. Ultimately, the priority remains ensuring timely vaccination with an appropriate, recommended vaccine.
Pharmacy Times: Only about one-third of older adults received a COVID-19 vaccine last season. What can pharmacists do at the counter to close that gap heading into the 2026-2027 season?
Ceddia: The vaccination gap among older adults remains a significant public health concern, particularly given their increased vulnerability to severe COVID-19 outcomes and hospitalization.
Pharmacists are uniquely positioned to help close this gap. As among the most accessible and trusted healthcare professionals, they have frequent opportunities to engage older adults, particularly those managing chronic conditions. Proactive, personalized recommendations, routine assessment of vaccination status, and open conversations addressing questions about vaccine effectiveness and safety can help build confidence and support informed vaccination decisions.
Importantly, we should move the conversation beyond preventing infection to protecting what matters most to older adults: their health, independence, and quality of life. By making vaccination discussions a routine part of patient interactions and reducing barriers to access, pharmacists can help translate everyday encounters into opportunities for timely vaccination.
Ultimately, closing the vaccination gap requires both continued innovation in vaccine protection and ensuring that eligible individuals have the information and access they need to benefit from it.
